Ligon Discovery, Lycera Partner to Develop Drugs for Immune Disorders

Terms of the deal call for Ligon to use its small-molecule microarray platform to screen protein targets that Lycera believes are critical to the development of certain immune disorders.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.